.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Farmers Insurance
Harvard Business School
Merck
Fish and Richardson
McKesson
Healthtrust
Accenture
Covington
Teva

Generated: November 21, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020873

« Back to Dashboard
NDA 020873 describes ANGIOMAX, which is a drug marketed by The Medicines Co and is included in one NDA. It is available from two suppliers. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the ANGIOMAX profile page.

The generic ingredient in ANGIOMAX is bivalirudin. There are thirteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the bivalirudin profile page.

Summary for 020873

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:2
Formulation / Manufacturing:see details

Pharmacology for NDA: 020873

Mechanism of ActionThrombin Inhibitors

Suppliers and Packaging for NDA: 020873

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ANGIOMAX
bivalirudin
INJECTABLE;INTRAVENOUS 020873 NDA AUTHORIZED GENERIC Sandoz 0781-3158 0781-3158-95 10 VIAL, SINGLE-USE in 1 CARTON (0781-3158-95) > 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-USE (0781-3158-94)
ANGIOMAX
bivalirudin
INJECTABLE;INTRAVENOUS 020873 NDA AUTHORIZED GENERIC Sandoz 0781-9158 0781-9158-95 10 VIAL, SINGLE-USE in 1 CARTON (0781-9158-95) > 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-USE (0781-9158-94)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INTRAVENOUSStrength250MG/VIAL
Approval Date:Dec 15, 2000TE:APRLD:Yes
Patent:► SubscribePatent Expiration:Jan 27, 2029Product Flag?Substance Flag?Delist Request?Y
Patent:► SubscribePatent Expiration:Jan 27, 2029Product Flag?Substance Flag?Delist Request?Y

Expired Orange Book Patents for NDA: 020873

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
The Medicines Co
ANGIOMAX
bivalirudin
INJECTABLE;INTRAVENOUS020873-001Dec 15, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Accenture
Daiichi Sankyo
Farmers Insurance
Harvard Business School
McKesson
Novartis
Fuji
Queensland Health
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot